For the year ending 2025-12-31, SNDX had -$19,268K decrease in cash & cash equivalents over the period. -$323,167K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -285,422 |
| Depreciation | 6 |
| Accretion of investments | 10,753 |
| Non-cash operating lease expense | 946 |
| Stock-based compensation | 47,503 |
| Amortization of debt issuance costs | 228 |
| Provision for credit losses | 3,667 |
| Inventory reserves | 163 |
| Accounts receivable | 30,394 |
| Inventory | 32,091 |
| Prepaid expenses and other current assets | 14,542 |
| Collaboration (payable) receivable, net | -42,976 |
| Other receivable | 6,436 |
| Other assets | 0 |
| Accounts payable | 4,954 |
| Accrued expenses and other current liabilities | 42,167 |
| Net cash used in operating activities | -322,980 |
| Purchases of property and equipment | 187 |
| Purchases of short and long-term investments | 195,807 |
| Proceeds from maturities of short-term investments | 486,030 |
| Net cash provided by (used in) investing activities | 290,036 |
| Proceeds from issuance of common stock in follow-on public stock offering, net-Follow On Public Offerings | 0 |
| Proceeds from issuance of common stock in follow-on public stock offering, net-At The Market Stock Offering | 0 |
| Proceeds from purchase and sale agreement, net | 0 |
| Proceeds from espp | 1,538 |
| Proceeds from stock option exercises | 12,138 |
| Net cash provided by financing activities | 13,676 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -19,268 |
| Cash, cash equivalents and restricted cashbeginning of year | 154,300 |
| Cash, cash equivalents and restricted cashend of year | 135,032 |
Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (SNDX)